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Abstract
The SCL (TAL1) transcription factor is a critical regulator of haematopoiesis and its expression is tightly controlled by
multiple cis-acting regulatory elements. To elaborate further the DNA elements which control its regulation, we used
genomic tiling microarrays covering 256 kb of the human SCL locus to perform a concerted analysis of chromatin structure
and binding of regulatory proteins in human haematopoietic cell lines. This approach allowed us to characterise further or
redefine known human SCL regulatory elements and led to the identification of six novel elements with putative regulatory
function both up and downstream of the SCL gene. They bind a number of haematopoietic transcription factors (GATA1,
E2A LMO2, SCL, LDB1), CTCF or components of the transcriptional machinery and are associated with relevant histone
modifications, accessible chromatin and low nucleosomal density. Functional characterisation shows that these novel
elements are able to enhance or repress SCL promoter activity, have endogenous promoter function or enhancer-blocking
insulator function. Our analysis opens up several areas for further investigation and adds new layers of complexity to our
understanding of the regulation of SCL expression.
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Introduction
Understanding the molecular events which occur as stem cells
differentiate into committed cell lineages is a fundamental issue in
cell biology. It has been shown that the SCL (TAL1) gene is
central to the mechanisms whereby pluripotent stem cells
differentiate into haematopoietic stem cells (HSCs) that give rise
to the various blood lineages. While this process is thought to be
tightly regulated at the level of gene expression, the exact ways in
which SCL helps direct this process are not well understood.
The SCL gene encodes a bHLH transcription factor (TF) which
is normally expressed in blood, endothelium and various areas of
the central nervous system. In the haematopoietic compartment,
SCL is expressed in multipotent haemangioblasts and HSCs, in
erythroid and megakaryocytic progenitors, and mast cells. SCL is
required during embryonic stem (ES) cell differentiation [1,2] and
for the establishment of all haematopoietic lineages [3–6], but is
not essential for self-renewing of HSCs [7]. Recently it has been
shown that expression of either SCL or the highly related bHLH
TF Lyl1 is required for maintenance of HSCs [8]. SCL expression
is required for normal differentiation of erythroid and megakar-
yocytic lineages [7,9], whereas inappropriate expression during
T-cell differentiation leads to T-cell acute lymphoblastic leukemia
(T-ALL) [10].
Evidence suggests that the transcriptional regulation of SCL is
tightly controlled in all of its biological roles. SCL is transcribed
from two promoters (1a and 1b) located at the 59 end of the gene
[11], and an additional promoter within exon 4 [12]. The analysis
of accessible chromatin using DNase I hypersensitive assays,
comparative sequence analysis and chromatin immunoprecipita-
tion (ChIP) in combination with real-time PCR has led to the
identification of additional regulatory elements [13–15] which
have activity in transfection assays or direct SCL expression into
specific compartments of its normal expression pattern in
transgenic mice. However, the elaborate nature of the cis- and
trans-acting events which control the concerted activity of all of
these elements remains unclear.
The use of genomic microarrays in combination with methods
such as chromatin immunoprecipitation (ChIP-chip) [16–18], are
powerful high-throughput approaches which allow events associated
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with the transcription of genes and the activity of their regulatory
sequences to be elucidated in vivo. In the present study, a tiling path
genomic microarray spanning 256 kb of the human SCL locus was
constructed and used in combination with ChIP and chromatin
accessibility assays to study the full complement of cis- regulatory
elements associated with the transcriptional regulation of SCL and its
flanking genes in haematopoietic cells. From this analysis, known
SCL regulatory regions and a number of novel regulatory elements,
which lay both upstream and downstream of SCL, were identified
and further characterized. The identification and characterisation of
these regulatory elements, and their relevance to SCL expression and
regulatory control are discussed.
Results
We constructed a tiling microarray across 256,636 bp of the
genomic region containing the human SCL locus at an average
resolution of 458 bp. The tiling array encompassed SCL and all of
its known regulatory sequences, and the neighbouring genes
MAP17 (PDZK1IP1) and SIL (STIL), and the 59 end of the
housekeeping KCY (CMPK, UCK) gene, all of which are
expressed during haematopoiesis [14]. We also included genomic
regions covering the genes for CYP4A22 and most of CYP4AZ1
located downstream of MAP17, which are not appreciably
expressed during haematopoiesis [14]. The hybridization of
fluorescently-labelled unamplified ChIP DNAs, coupled with a
highly sensitive and quantitative array platform [19], allowed us to
identify reproducibly (Figure S1), and validate with real-time PCR
(Figure S2), a wide range of regulatory features across the SCL
locus as described below.
Histone Modifications Define Known and Novel Regions
of Regulatory Function
It is well established that histone H3 post-translational
modifications play an intrinsic role in transcriptional regulation
and mark both active and silent regulatory sequences and/or
entire gene loci [20–26]. To delineate novel regulatory elements
across the SCL locus, we profiled activating and repressive histone
marks in the SCL-expressing K562 cell line (Figure 1). K562 cells
represent a well-characterized model of the erythroid lineage and
show a high concordance with respect to ChIP-chip data from
primary mammalian erythroid cells at both the gene level and
genomewide [24,27-31].
We identified a number of regions of clearly discernable
enrichments for the activating modifications histone H3 K9/K14
di-acetylation (H3 K9/K14ac) and histone H3 K4 methylation
(H3 K4me1/me2/me3), many of which marked regulatory
regions which had been studied previously at the human SCL
locus. These included the promoters of the KCY, SIL and SCL
genes that are expressed in K562 (as determined by Affymetrix
GeneChip expression profiling [24]), and at sites within the SCL
transcript known to have promoter or enhancer activity [the exon
4 promoter (PE4) and the +1, +3 regions]. Enrichments were also
found at the SCL haematopoetic stem cell enhancer (+19/+20/
+21) [14,32], the SCL erythroid enhancer (+50) [14,15], the
MAP17 promoter and its enhancer (PM17 and +40 respectively)
[31], and the27 and210 regions [14,33,34]. All these regions are
named according to their distances downstream (+) or upstream
(2) in kb from the human SCL pro1a (P1a in Figure 1).
In addition, we detected a number of peaks of H3 K4
methylation and H3 K9/K14 diacetylation across the SCL locus
which had not been identified by anymeans in previous studies. The
most prominent of these was located 53 kb downstream of SCL P1a
(+53) and showed particularly high levels of H3 K4me3. This region
is also associated with a number of novel transcripts of unknown
function (denoted a, b and c in Figure 1). We also found sites of
enrichments, most prominent with H3 K4me2 and H3 K4me1, at
213, and 226, upstream of SCL P1a, and at +39, +45, and +57.
The latter one of these, +57, was also associated within a region
which showed a transition from low levels of the repressive mark H3
K27me3 over the transcriptionally-active SCL, MAP17, SIL and
KCY genes to higher levels over the silent CYP4AZ1 and
CYP4A22 genes (Figure 1). Transitions in levels of H3 K27me3
have previously been associated with CTCF-binding and insulator
activity, demarcating boundaries between transcriptionally-active
and silent gene loci [35]. These patterns of activating and repressive
histone marks are consistent with expression patterns of genes at the
SCL locus [14]. More importantly, they define discrete blocks of
active chromatin and repressive chromatin, demarcated at, or near,
+57 2 suggesting that this region may define a putative insulator.
The Transcriptional Machinery, CTCF and TFs Define
Regions with Regulatory Function
We defined further both known and novel regulatory sequences
at the SCL locus by associating them with a number of biologically
important proteins involved in transcriptional regulation. These
included RNA polymerase II (PolII) and TAFII 250 (also know as
TAF1), the insulator protein CTCF [36,37], and transcription
factors which have important roles in haematopoeisis.
As we anticipated, prominent peaks of enrichment for PolII and
TAFII 250 were found at or near the promoters of SCL, SIL and
KCY (Figure 2) as these genes are transcribed in K562 to relatively
high levels (data not shown). Less significant peaks were associated
with the MAP17 promoter (PM17), the transcript from which is
expressed at significantly lower levels [14]. Both PolII and TAFII
250 enrichments extended from SCL P1a to the +3 region, with
PolII extending to SCL PE4. We also detected peaks of PolII and
TAFII 250 binding at other known and putative SCL regulatory
elements: at the stem cell enhancer, the 210 region, and across
3 kb spanning the erythroid enhancer (+50 to +53). The binding of
the PolII machinery at enhancers is well-known [38].
By contrast, CTCF showed patterns of binding consistent with
H3 K27me3 patterns (see above) and/or its known role as an
insulator which defines transcriptional domains [35,36]. Prominent
peaks of enrichment were found at a novel region between SCL and
SIL 31 kb upstream of SCL pro1a (231) and at +57, between the
erythroid enhancer at +51 and CYP4A22. Similarly, prominent
peaks were found within CYP4A22, CYP4AZ1 and between or
within SIL and KCY. CTCF was also found bound at +53, the
MAP17 enhancer (+40), and the 27 region. Three of these sites
(+57, +53 and +40) were also confirmed experimentally or predicted
in other studies based on the consensus binding motif of CTCF [36].
The transcription factors GATA1, LMO2, E2A, LDB1 and SCL
itself are known to associate in a DNA-binding complex in erythroid
cells [39,40] which regulates gene expression [41]. Regions of
statistically significant enrichments (Table S1) for all or some of
these TFs were found at a number of SCL regulatory sequences
including the SCL P1a, PE4, 27 and 210 regions and most
prominently all were found bound at +51 (Figure S3), one kb
downstream from the known peaks of histone H3 K9/K14ac [14]
and H3 K4me1/me2 or me3 associated with the erythroid
enhancer at +50.
Chromatin Architecture Facilitates Accessibility to
Regulatory Regions
It has been demonstrated that the detection of decreased levels
of nucleosomes (i.e., nucleosome depletion) [24,25,42–45] or an
Regulatory Landscape of SCL
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Figure 1. Histone H3 modification profiles across the human SCL locus in the K562 cell line. The modifications studied are named at the
left of each panel. Dots on the solid joined-up lines represent the data obtained for each genomic tiling array element. In each panel, the x-axis is the
genomic sequence co-ordinate (NCBI build 35) and the y-axis is the enrichment obtained in ChIP-chip assays expressed in log2 scale. Schematic
diagram at the bottom of the figure shows the genomic organisation of SCL and its neighbouring genes. Exons are shown as vertical blocks with
gene names and direction of transcription shown above. Transcripts denoted by a,b and c refer to transcripts of unknown function (see also text).
Vertical lines at the bottom (with dotted lines through all the panels) show the location of known and novel regulatory regions at the SCL locus.
Promoters are denoted by P. Other nomenclature refers to the distance in kb from SCL pro1a (P1a). Novel regions are highlighted in bold at the
bottom and with arrows at the top of the figure.
doi:10.1371/journal.pone.0009059.g001
Regulatory Landscape of SCL
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inability to detect sub-types of nucleosomes (using standard ChIP
methods) [46] may be a general feature of active genes and their
active regulatory sequences in eukaryotic genomes. We found
that nucleosome architecture at the human SCL locus was in
agreement with these models. ChIP-chip profiles in K562 cells for
the nucleosomal components histone H3 and histone H2B were
compared with the results of our FAIRE chromatin fractiona-
tion assays (Figure 2). FAIRE assays allow DNA segments which
Figure 2. CTCF, PolII and TAFII 250 binding, chromatin accessibility and nucleosome density profiles across the human SCL locus in
the K562 cell line. Assays used are named at the left of each panel. Dots on the solid joined-up lines represent the data obtained for each genomic
tiling array element. In panel E, the profiles for histone H2B and histone H3 are shown as dotted joined-up line with triangles and solid joined-up lines
with dots for H2B and H3 respectively. All other aspects of the figure are as in Figure 1.
doi:10.1371/journal.pone.0009059.g002
Regulatory Landscape of SCL
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are less readily cross-linked with proteins after formaldehyde
treatment (i.e., regions of accessibility or DNase I hypersensitivity)
to be physically separated from bulk cross-linked chromatin using
phenol-chloroform fractionation [47,48]. FAIRE peaks across the
SCL locus coincided with DNase I hypersensitivity sites found in
K562 [31,49], and there was a very high inverse correlation
between nucleosome density and FAIRE (R=20.861) across the
SCL locus (Figure S4), demonstrating that FAIRE peaks identified
regions of accessible chromatin which had lower levels of
nucleosomes.
We also found that both known SCL regulatory elements and
novel regions identified in the present study exhibited lower levels
of nucleosomes and higher levels of chromatin accessibility in
K562 cells. These included the promoter regions of the KCY, SIL
and SCL genes and within transcribed sequences at the 59 end of
SCL. Low levels of nucleosomes were also found at the erythroid
enhancer (at +51 but low nucleosome levels extended from +50 to
+53), the +57 region, the MAP17 enhancer, and the 27, 210 and
231 regions. These novel regions were also bound by components
of the general transcriptional machinery and/or TFs, thus
possessing similar structural and functional features as known
SCL regulatory regions. Although these regions showed lower
levels of nucleosome occupancy, they also showed high levels of
activating histone modifications (H3 K4me1,2 or 3 and H3 K9/
K14ac) – suggesting that whilst there were fewer nucleosomes in
these regions, the nucleosomes which were localised there had very
high propensities for being modified.
Structural and Functional Analysis of Novel Regulatory
Elements
We used a number of computational and experimental
approaches to further assess the regulatory nature of the novel
regions we had identified. This analysis included the novel regions
that were either upstream or downstream of SCL and up to and
including the +57 and 231 regions respectively. Both +57 and
231 bind CTCF and define an 88 kb regulatory domain
containing SCL, MAP17 (thought to be co-regulated with SCL
[14]) and all known SCL regulatory elements. None of the nearby
genes outside of this domain are thought to share regulatory
elements with SCL, suggesting that CTCF at these sites marks the
location of insulators [50]. We examined seven regions in this
interval which had previously not been analysed in human
haematopoietic cell types. These included +57, +53 and +51
located near the +50 erythroid enhancer, and 27, 210, 213 and
231 upstream of SCL.
It has been established by us and others that active promoters
and enhancers can be discriminated from each other based on
levels of activating histone H3 modifications (H3 K9/K14ac and
H3 K4me1,2,3) [22,24–26,51]. With this in mind, we used
hierarchical clustering of our data across the SCL locus for these
modifications as a means of attributing putative promoter and
enhancer function to these novel regions (Figure 3). Microarray
tiles containing DNA sequences for known regulatory elements
and novel ones formed two distinct clusters with differing histone
modification signatures. The first cluster showed hallmarks of
promoters [24,25] with high levels of H3 K9/K14ac and H3
K4me2,3 and lower levels of H3 K4me1. Contained within this
cluster were microarray tiles for promoters and adjacent sequences
for SCL, KCY and SIL, the +3 region, whose proposed function is
consistent with promoter activity [52], and the +53 region located
in the vicinity of novel transcripts.
The second cluster showed signatures of active enhancers
[24,25] with high levels of H3 K4me1,2 and lower levels of H3
K9/K14ac and H3 K4me3. Contained within this cluster were
microarray tiles for known SCL and MAP17 enhancers (+19/
+20/+21, +40 and +50), a number of novel regions (27, 210,
213, +39, +45, +51) and two promoters which were either
inactive or had low activity in K562 (SCL PE4 and PM17). Thus,
these novel regions had attributes of active enhancers in K562 and
low activity promoters also had an active enhancer-like histone
modification pattern. However, neither the 231 or +57 regions,
which both bind CTCF, were found in this cluster suggesting that
these regions may be functionally distinct from active enhancers.
Given that several of the novel regions had epigenetic hallmarks
of either promoter and enhancer activity, we analysed a panel of
transient luciferase reporter constructs in K562 (erthyroid/SCL +)
and HPB-ALL (lymphoid/SCL -) to ask whether these novel
sequences could enhance or drive gene expression in vivo and
whether their effects were lineage-specific or specific to SCL
regulation. We tested whether the +53 region had promoter
activity, and whether the six other regions (+57, +51, 27, 210,
213, and 231) could enhance luciferase expression under the
control of the SCL pro1a and SV40 promoters (Figure 4). Of those
regions assayed for enhancer activity, four were able to increase
luciferase expression levels under the control of the SCL pro1a
and/or SV40 promoters in either K562 or HPB-ALL (Figure 4a).
The +51 and 210 regions showed enhancer activity on both the
SV40 and SCL pro1a promoters, whereas 27 and 231 showed
enhancer activity on only the SV40 promoter (27) or only on SCL
pro1a respectively (231). 231, 210 and 27 exhibited enhancer
activity in both K562 and HPB-ALL, while +51 was only active in
K562, suggesting it had erythroid-specific enhancer activity. The
213 region showed repressor activity on both the SCL pro1a and
SV40 promoters by reducing luciferase activity in the range of 42–
57% (stastically significant decreases in both K562 and HPB-ALL)
indicative of repressor activity in both cell types. However, the +57
region was not able to modulate luciferase expression on either
promoter.
The +53 region exhibited low levels of promoter activity in both
cell lines and in both orientations when compared to the activity of
SCL pro1a and the SV40 promoter at driving luciferase
expression (Figure 4b). However, this activity was statistically
significant above background, indicative of +53 being a bidirec-
tional promoter. This is consistent with this region co-localising
with lowly expressed novel transcripts (see below), and having a
histone modification signature of promoters.
We demonstrated that CTCF was bound to 231, +53, +57 (see
above and Figure 2). Given the known role of CTCF binding at
regions exhibiting enhancer-blocking insulator function [37], we
assayed for any enhancing-blocking activity for these three regions
as well as a region upstream of the MAP17 promoter which also
showed CTCF binding in our analyses, as well as enhancer activity
in previous studies [31]. Enhancer-blocking activity was based on
the ability of a test sequence being able to block enhancer activity
when placed between a known enhancer capable of driving
expression of geneticin (G418)-resistance in the K562 erythroid
cell line. By measuring the number of K562 colonies obtained for
each of the constructs under selection with geneticin, we were able
to demonstrate enhancer-blocking activity for all four of the test
regions (Figure 4c), consistent with these regions having insulator
activity.
Computational analysis of the novel elements we had identified
revealed DNA sequence-based features indicative of conserved
regulatory function across mammalian species. Novel regions
showed computational five-way regulatory potential [53,54] (data
not shown) and some, but not all, showed conservation of relevant
DNA sequence motifs. In particular, we identified a number of
highly conserved binding motifs in the 213 repressor region,
Regulatory Landscape of SCL
PLoS ONE | www.plosone.org 5 February 2010 | Volume 5 | Issue 2 | e9059
Figure 3. Treeview diagram of hierarchical clustering of genomic tiles across the human SCL locus for histone modifications in the
K562 cell line. Each tile is represented by a horizontal bar and is shaded in red scale or green scale to denote level of enrichment or depletion
respectively. The tree diagram is shown to the left of the figure. Two branches of the tree and the histone modifications studied are shown in the
enlarged panel to the right of the figure. Each genomic tile in the enlarged panel is named according to its distance in kb relative to SCL pro1a or to
the promoter of its closest known gene. Tiles representing SCL known and novel regulatory elements are denoted by an arrow and highlighted in
bold.
doi:10.1371/journal.pone.0009059.g003
Regulatory Landscape of SCL
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Figure 4. Transient reporter assays of novel regulatory elements at the human SCL locus. A. Enhancer/repressor activity of six novel
regulatory elements in K562 (erythroid) and HPB-ALL (lymphoid) cell lines. The y-axis shows the fold increase/decrease in luciferase activity relative to
the pGL3 basic negative control construct (not shown). The x axis shows constructs under the control of the SV40 promoter (SV40 pro) or the
promoter 1a of SCL (SCL pro1a). All constructs under the control of these two promoters are named according to the region being tested based on
their distance in kb from the SCL pro1a (2 = upstream; + = downstream). The SV40pro and SCLpro1a control lanes shown were derived from
transfections with constructs containing a sequence having no regulatory function cloned into the BamHI site. Luciferase expression for the SV40
promoter in combination with the SV40 enhancer (SV40 pro/en) is also shown as a positive control. Standard error bars are shown. B. Promoter
assays of the +53 region in K562 (erythroid) and HPB-ALL (lymphoid) cell lines. The y-axis shows the fold increase/decrease in luciferase activity
relative to the pGL3 basic negative control construct. The x axis shows luciferase expression driven by pGL3 basic, SCL pro1a only (SCL pro1a positive
control), SV40 pro (SV40 promoter positive control), and the two +53 constructs (SCL+53u and SCL+53d). The +53 region was cloned in one (u) or the
other (d) orientation. Standard error bars are shown. C. Enhancer blocking assays of regions at the SCL locus which bind CTCF in the K562 cell line.
The y-axis shows enhancer blocking activity (G418-resistant colony counts) for the pNI and pNI-CD (negative and positive controls) and four putative
insulator regions from the human SCL locus. Insulator constructs are named according to the region being tested based on their distance in kb from
the SCL pro1a (2 = upstream; + = downstream). Standard error bars are shown. Note: Enhancer blocking assays were performed only in the K562
cell line as expression of the pNI-based vector is regulated by the murine HS2 b-globin enhancer which is active only in erythroid cells.
doi:10.1371/journal.pone.0009059.g004
Regulatory Landscape of SCL
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including an 11 bp sequence for the ets family ETV6/7 proteins
(Figure S5). ETV6 (TEL1) and ETV7 (TEL2) are transcription
factors, expressed during haematopoiesis and have been shown to
exhibit strong repressor activity in vivo [55,56]. The +51 region
showed a striking conservation of three GATA and other TF
binding sites (Figure S6). One of these GATA sites was contained
within a 20 bp sequence containing a GATA/E-box composite
site which showed the canonical hallmarks of the SCL-containing
erythroid complex [39,40].
Previous work had suggested that the erythroid enhancer, which
directs SCL expression during primitive and definitive erythropoi-
esis [14,15] was defined at +50 [14]. However, our analysis
demonstrates that the 1 kb region adjacent to +50, at +51, contains
conserved DNA sequence motifs which are likely to be the core site
of binding for the SCL-containing erythroid complex (henceforth,
the core erythroid enhancer is renamed the +51 region). This is
consistent with recent studies of the murine equivalent of the SCL
erythroid enhancer [15]. However, the presence of a bi-directional
promoter at +53, highlights the complexity of the regulatory
landscape around the erythroid enhancer.
The Regulatory Complexity at the SCL Erythroid Enhancer
With this is mind, we sought to more accurately define the
regulatory environment of the +51 SCL erythroid enhancer in cell
lines where it was either active or inactive. Using ChIP-chip, we
examined regulatory features across a 4 kb region (+50 to +53) in
three non-erythroid haematopoietic cell lines (U937, HL-60 and
HPB-ALL) which do not express SCL and compared these
features with those found in K562.
The SCL-containing erythroid complex (SEC) was bound at
+51 in K562 (Figure 5a) and not in the other cell lines (U937,
HL60, HPB-ALL) (not shown). We also confirmed that the SEC
was present at +51 in a second erythroid cell type HEL 92.1.7
which expressed SCL [14] (Figure S7). CTCF was bound to the
+53 region in all these cell lines (K562 and U937 shown in
Figure 5b), approximately 500 bp from the region shown to have
bi-directional promoter activity. TAFII 250 and PolII showed
binding patterns consistent with the location of the bi-directional
promoter at +53 in all of the cell lines (K562 and U937 shown in
Figure 5c and 5d respectively). In K562, PolII was also bound to
the +51 erythroid enhancer, along with TAFII 250 at +50. These
data suggest that the +51 erythroid enhancer, specifically, is
responsible for binding the SCL erythroid complex and also
recruits PolII in erythroid cells only - this recruitment extends to
+50, towards the SCL gene, and includes TAFII 250. The +53
promoter, on the other hand, is involved in recruitment of PolII
and TAFII 250 in all of the cell lines with a bias towards
recruitment in the opposite direction, and includes the binding of
CTCF near, but not at, the promoter.
This bipartite structure was re-iterated when we examined
histone H3 K4me and histone H3 K9/K14ac. All of the cell lines
showed patterns for these histone marks at or close to the +53
region consistent with the activity of the promoter. Only K562
showed increased levels of histone modifications consistent with
the activity of the enhancer at +51 extending to +50. We also
confirmed that transcripts produced at or near the +53 element
were present in all of these cell lines. Their expression, however,
was at low levels relative to SCL expression (see Figure S8 for
K562 data), or the expression of the b-actin gene (not shown).
Discussion
Over the last twenty years, a number of approaches have been
used to characterise regulatory elements at the SCL locus. In many
of these approaches, a variety of human and murine haemato-
poietic cell lines have been used to identify regions capable of
mediating regulatory activities on SCL [12,14,32,33,49,52]. We
describe here the first comprehensive analysis using ChIP-chip
approaches and downstream analyses to facilitate the character-
ization of a further set of genomic cis-acting sequences which
underlie the regulation of gene expression at the human SCL
locus. Patterns of histone modifications, chromatin accessibility/
nucleosome density and the binding of regulatory/transcriptional
proteins were obtained across 256 kb of the locus in the K562
haematopoietic cell line. Based on this, six novel human regulatory
elements (named 231, 213, 210, 27, +53, +57) found either
upstream or downstream of SCL are characterised here, and one
existing element, the SCL erythroid enhancer (+51), has been re-
defined. This study effectively more than doubles the number of
regulatory elements localised to the human SCL locus, and
emphasises the impact that such approaches have at rapidly
defining the regulatory architecture of gene loci. In addition to
these, we identified a further 3 regions of interest (226, +39, +45)
by virtue of their association with peaks of histone modifications;
we have not examined these in this study but they warrant further
investigation. Our analysis also redefines the size of what we
consider to be the SCL regulon – to a region encompassing 88 kb
between the 231 element upstream of SCL and the +57 element
downstream of the +51 erythroid enhancer. Both 231 and +57
bind CTCF - consistent with the role of CTCF-binding elements
defining regulatory domains [35,36]. Previous studies have
suggested that the SCL regulon encompasses 65 kb [57], but this
figure seems to be an underestimate given that, while it includes
231 within its boundaries, it excludes the +51 erythroid enhancer,
and the +53 and +57 elements. Whilst the exact roles of +53 and
+57 with respect to SCL activity have yet to be determined, we
cannot exclude them from the SCL regulon until further studies
are performed (see also discussion below).
The overall general regulatory features of these novel elements,
and other known elements, at the SCL locus are in agreement with
accepted models of regulatory function. Firstly, they are associated
with histone H3 K4me, with enhancers and promoters showing
biases towards H3 K4me1 and H3 K4me3 respectively. Second,
they are in regions of open chromatin, characterised by low
nucleosome density and FAIRE enrichments and correlate to
positions of known hypersensitive sites [49]. Finally, given their
open chromatin conformation, they bind transcription factors and
components of the transcriptional machinery, the binding sites for
some of which are conserved across other mammalian species.
Taken together with our report construct transfection data in
K562, our ChIP-chip analyses identify and characterise compo-
nents of the regulatory environment of the human SCL locus,
some or all of which may control SCL expression. Given that our
reporter assays in K562 do not necessarily recapitulate the
function of these components in the correct biological environ-
ment, it will be necessary to perform further functional studies in
vivo to determine their lineage specificity and roles in regulating
SCL expression. These lines of investigation would include ChIP
analysis in primary haematopoietic cells, removal (i.e., knockout)
or mutation of cis-elements, or analysis of reporter transgenes
under the regulatory control of these elements. Such studies have
been performed for several of the known cis-elements which direct
SCL expression in mouse or Xenopus [15,32,34,57–61] subsequent
to their identification and initial characterization in cell lines.
Upstream of SCL we identified three enhancers and one
repressor element at 27, 210, 231 and 213 respectively. The
element at213 is capable of repressing luciferase expression under
the control of either the SCL pro1a or SV40 promoters in
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Figure 5. ChIP-chip analysis of the human SCL erythroid enhancer region in SCL-expressing and non-expressing haematopoietic
cell lines. A. Binding of the SCL-containing erythroid complex (SEC) of transcription factors in the K562 cell line. E47 and E12 are two isoforms of
E2A. B. CTCF binding in the K562 and U937 cell lines. C. TAFII 250 binding in the K562 and U937 cell lines. D. PolII binding in K562 and U937 cell lines.
E. Histone H3 K4me3 in the K562, U937, HPB-ALL and HL-60 cell lines. F. Histone H3 K4me2 in the K562, U937, HPB-ALL and HL-60 cell lines. G.
Histone H3 K4me1 in the K562, U937, HPB-ALL and HL-60 cell lines. H. Histone H3 K9/K14ac in the K562, U937, HPB-ALL and HL-60 cell lines. All
enrichments obtained in ChIP-chip assays are expressed in log2 scale in the figure. Schematic at the bottom shows the 4 kb of genomic DNA
surrounding the SCL erythroid enhancer. Genomic sequence co-ordinates are from NCBI build 35. Numbering of the blocks of DNA (with dotted lines
through all the panels) refers to the distance in kb from SCL pro1a. The vertical dotted lines are positioned at the mid-point of each of the 1kb blocks
and do not define positions of regulatory regions per se.
doi:10.1371/journal.pone.0009059.g005
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erythroid (K562) and lymphoid (HPB-ALL) cells, consistent with
the idea that it may regulate SCL expression when it is expressed
in the erythroid lineage, and contribute to its silencing in the
lymphoid lineage. It is the second repressor element identified at
the SCL locus - the first being found in the 39 UTR of the SCL
gene [12]. Whilst we have not confirmed this here because of a
lack of an antibody for ETV6/7 which works well in ChIP, the
ETV6/7 (TEL1/TEL2) proteins are still likely candidates to
mediate the activity of this repressor element. The 210 region is
capable of enhancing luciferase expression under the control of
both the SCL pro1a and SV40 promoters in human erythroid cells
and the endogenous 210 binds a number of transcription factors
including GATA1, E2A and LDB1 in vivo. A murine genomic
sequence equivalent to 210 has been shown to enhance
expression of murine SCL in erythroid cells [33]. The 27 element
also has enhancer activity in reporter assays in K562 and binds
GATA1 in vivo. However, whilst 27 enhanced luciferase
expression under the control of the SV40 promoter, it was not
capable of enhancing reporter expression under the control of the
SCL pro1a, suggesting that the local chromatin environment may
be important in regulating its activity in vivo or that it regulates
SCL activity but not through enhancement of SCL pro1a.
Furthermore, the fact that both 210 and 27 may also be active
in the lymphoid lineage (by virtue of their activity in HPB-ALL
cells) also suggests that, unlike +51 erythroid enhancer, their
regulation of SCL is not lineage-specific. Conversely, the 231
element was able to enhance luciferase expression under the
control of SCL pro1a, but not under the control of the SV40
promoter, suggesting that whilst the chromatin environment may
not be important for its activity, its role as an enhancer has
additional specificity for SCL pro1a.
The 27 and 231 enhancers both bind CTCF in vivo in
erythroid cells and, in the case of the latter, CTCF binding is
highly enriched in ChIP-chip. Spatially, the binding of CTCF at
these enhancers suggests that its role is not related to insulator
activity at these sites, but is that of a transcription factor [37].
However, the binding pattern of CTCF at 231 is not defined by a
single peak of enrichment in ChIP-chip - it is likely to bind to
several sites over at least 2 kb interval centered at 231. This
suggests that its role at this element may be complex and may
suggest that other elements are juxtaposed nearby. This model,
and the fact that no other regulatory sequences for SCL have been
identified distal to231 (towards SIL), would be consistent with the
binding of CTCF at 231 or nearby sequences defining an
insulator boundary between SCL regulatory elements and those of
the neighbouring SIL gene. Enhancer blocking assays confirmed
that 231 does indeed have insulator activity and supports our
interpretation of 231 as defining the SIL/SCL regulatory
boundary.
We also detected a novel region which binds CTCF
downstream of SCL at +57. Unlike 231, this region does not
demonstrate enhancer activity in reporter assays, but does have
insulator enhancer-blocking activity. The location of +57, which
coincides with a boundary between high levels of H3 K27me3 on
one side and H3 K4me1,2 on the other in K562, is highly
suggestive of a role as an insulator also with barrier activity. An
insulator at this location would be required for the compartmen-
talisation of elements involved in SCL regulation (including the
+51 region six kb away) from those of CYP4A22 as well as
preventing the spread of repressive histone marks into the SCL
regulatory domain. However, given that +51 is located between
the MAP17 gene and an active bi-directional promoter at +53, the
possibility that CTCF may mediate other insulator functions to
compartmentalise the regulation of these genes, would also be
necessary. The binding of CTCF near +53 and upstream of the
MAP17 promoter at/near the recently identified MAP17
enhancer[31], both of which have insulator enhancer-blocking
activity, support this hypothesis and underlines the complexity of
the compartmentalisation required to delineate the SCL regula-
tory domain.
This complexity is no better exemplified than by the region
surrounding the erythroid enhancer at +51 (Figure S9). The
murine equivalent of this enhancer (SCL +40 in mouse), has been
shown to regulate SCL expression during primitive and definitive
erythropoiesis and in the midbrain [15]. Furthermore, the histone
modification profiles and TF binding of murine +40 and human
+51 [14,15] are in agreement with the results we described in
K562 and in cell types which do not express SCL. In human, the
+51 enhancer is flanked on one side by a bi-directional promoter
at +53, which is associated with transcripts of no known function.
These short transcripts (,500 bp) are spliced but have no
substantial open-reading frames, suggesting they may be non-
coding RNAs [62].
The erythroid enhancer is highly active in K562 cells at
enhancing reporter expression under the control of the SCL
pro1a and SV40 promoter. Along with the +53 promoter, +51
recruits PolII, although the recruitment to the enhancer element
is distinguishable from that to the +53. Mechanistically, this
suggests that the enhancer may be involved in the delivery of
PolII and TAFII 250 to the SCL promoters, but equally it could
be involved in recruitment of the transcriptional machinery to
+53, as the exact relationship between these two elements is not
yet known. Furthermore, whilst the roles of any ncRNAs
originating from +53 are not known, these may involve the
maintenance of an open chromatin status (in addition to the
presumptive insulator role of the +57 element) at one boundary of
the SCL regulatory domain, or transcriptional interference
regulating the +51 enhancer [63].
A further complexity of this region is that activating histone
modifications, TAFII 250 and PolII are also present at +50,
flanking the core erythroid enhancer, which are distinguishable
from peaks of enrichment at +51. Recent studies of the murine
SCL stem cell enhancer (+20 in human) have shown that
additional sequences flanking it specifically boost SCL activity in
vivo [64]. Transient reporter assays containing the murine
equivalents of both +50 and +51 also showed increased enhancer
activity compared with constructs lacking +50 [15]. Whether +50
represents an additional regulatory element or a ‘‘booster’’
element is not clear at this time.
The +51 erythroid enhancer also binds the SCL-containing
erythroid complex (SEC) in K562 cells. We have also confirmed
the binding of the SEC in another human erythroid cell line (HEL
92.1.7). These data point to the possibility that SCL regulates its
own expression, however, SEC binding in primary primitive
erythroblasts would be required to confirm SCL auto-regulation in
vivo. To date, there is evidence from analysis of the murine SCL
erythroid enhancer to support this hypothesis [15]. In HSCs,
activity of the SCL stem cell enhancer (+20/+21 in human) is
independent of SCL expression [59]. Our data are therefore
consistent with a model where once SCL expression has been
established in HSCs, maintenance of SCL expression during
differentiation towards erythroid cells is at least partly achieved
through an auto-regulatory feedback loop acting through the +51
erythroid enhancer and mediated by the binding of the SCL-
containing erythroid complex. We are currently exploring several
avenues of investigation to further understand the function of this
enhancer and the ever-increasing complexities of SCL transcrip-
tional regulation.
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Materials and Methods
SCL Tiling Array Construction
Oligonucleotide primers pairs (Table S2) were designed from
genomic sequence and used to prepare amplicons and arrays as
described elsewhere [19].
Chromatin Immunoprecipitation and FAIRE
Human cell line K562 [65] was cultured in DMEM, 9% fetal
calf serum, 1% penicillin-streptomycin and 2 mM L-glutamine.
Human cell lines HEL 92.1.7 [66], U937 [67], HL-60 [68], and
HPB-ALL [69] were cultured in RPMI 1640, fetal calf serum
(18% for U937, 9% for HEL 92.1.7, HL-60 and HPB-ALL), 1%
penicillin streptomycin and 2 mM L-glutamine. ChIP was
performed as described elsewhere [70]. ChIP antibodies are
described in Table S3. Ten micrograms of antibody was used in
each ChIP assay. Formaldehyde-based chromatin fractionation
assays (FAIRE) [47,48] were performed using cross-linked
chromatin prepared as for ChIP.
Fluorescent DNA Labelling, Microarray Hybridization and
Quantitation
Fluorescently-labelled DNA samples were prepared from
unamplified input/ChIP/FAIRE DNAs and hybridized to
microarrays for 45 hours using an automated hybridization
station (HS 4800TM, TECAN). Microarrays were scanned using
a ScanArray 4000 XL (Perkin Elmer). Mean spot intensities from
images were quantified using ProScanArrayH Express (Perkin-
Elmer) with background subtraction. Mean ratios and standard
deviations (SDs) for all array elements spotted in triplicate were
calculated and the datasets normalized to the median ratio per
hybridization. Final datasets for each assay were derived from the
mean values of three independent biological replicate experi-
ments. Transcription factor, RNA polymerase II (PolII) and
TAFII 250 ChIP-chip experiments were normalised with the
relevant antisera control datasets. Significant enrichments in
normalised transcription factor ChIP-chip experiments were
considered to be those values that were more than 4 standard
deviations away from the mean ratio of background levels.
Background levels were derived from genomic regions represent-
ed as SCL tiling arrays which did not contain known non-coding
regulatory sequences at the time of analyis (chromosome 1
genomic co-ordinates 47262288–47343557 and 47424426–
47489322 (NCBI build 35). FAIRE, histone modification and
histone H3/H2B enrichments/depletions were interpreted based
on visualizations of data plots.
Reporter Assays
Putative and known regulatory elements were tested in replicate
experiments for their ability to promote, enhance or repress the
expression of the firefly luciferase gene in pGL3 reporter construct
(Promega). For promoter assays, PCR products (Table S4) were
cloned upstream of the firefly luciferase gene into the HindIII and
KpnI cloning sites of the promoterless pGL3 basic vector. For
enhancer/repressor assays, PCR products (Table S4) were cloned
in the BamHI cloning site downstream of the firefly luciferase gene
under the control of either the SV40 promoter or SCL promoter
1a. Aliquots of 56106 K562 cells were transferred to Gene Pulsar
0.2 cm cuvettes (Bio-Rad) and transfected with 4 mg of luciferase
reporter construct and 1 mg of a control plasmid expressing b-
galactosidase using nucleofection (Amaxa, protocol T-016) and
cultured for 48 hours. Cell lysates were prepared with 100 mL of
1X lysis buffer (Promega). 20 mL of cell lysates were used for
luminescent b-galactosidase assays (Clontech) and luciferase assays
(Promega) using a luminometer (LB 930, Berthold). Luciferase
activities were then normalised with the corresponding b-
galactosidase values and expressed relative to the relevant negative
control experiment.
For enhancer-blocking assays, PCR products (Table S5)
spanning CTCF binding sites were cloned into the AscI site of
the vector pNI [71,72]. Each construct was linearised with SalI
and 1 mg was transfected (Amaxa, protocol T-016) into 16107
K562 cells. After 24 hr of recovery, cells were plated on soft agar
with geneticin (G418) (750 mg/ml). G418 resistant K562 colonies
were counted 2.5–3 weeks after selection and compared to results
obtained with pNI (‘‘insulator-less’’ vector) and pNI-CD (contain-
ing 2 copies of the 250 bp chicken b-globin core HS4 insulator).
Quantitative Real-Time PCR of ChIP DNAs and cDNA
K562 and HEL 92.1.7 ChIP and input DNAs were quantified
for genomic DNA sequences represented on the human SCL tile
path array. SyBr green PCR (Applied Biosystems) was performed
on a 7700 sequence detection system (Applied Biosystems). The
oligonucleotide primer pairs used are found in Tables S6 and S7
respectively. Each quantitative real-time PCR assay was per-
formed in triplicate. Fold enrichments were calculated as described
previously [14]. The mean quantitative PCR values were
normalised against the corresponding array data by deriving the
median ratio of both datasets and scaling the values accordingly.
Total cellular RNA from human cell lines was purified us-
ing TRIZOL reagent (Invitrogen) (www.sanger.ac.uk/Projects/
Microarrays/arraylab/methods.shtml). Single-stranded cDNA
from these RNAs was synthesized from 1 mg total RNA using
SuperScriptTM II RNase H2 reverse transcriptase according to
manufacturer’s instructions (Invitrogen). These cDNA were then
used to quantify the level of novel transcripts, SCL and the b-
actin control. The oligonucleotide primer pairs used are found in
Table S8. SyBr green PCR (Applied Biosystems) was performed
on a 7700 sequence detection system (Applied Biosystems). Ct
values were extracted and DCt values of transcripts a, b and c
calculated relative to the level of SCL and/or b-actin control.
Computational Analyses
Hierarchical clustering was performed using Cluster 3.0 [73]
(Euclidean distance similarity metric with average linkage) and
visualised with Java Treeview [74]. Comparative sequence
alignments of novel regulatory regions found in human, chimp,
mouse, rat and dog were obtained from the UCSC Genome
Browser (http://genome.ucsc.edu/). Transcription factor binding
sites were identified using the TFSEARCH (http://www.cbrc.jp/
research/db/TFSEARCH.html) [75,76] and TESS (http://www.
cbil.upenn.edu/tess/) [77] web servers. Five-way regulatory
potential scores [53,54] were visualized on the UCSC Genome
Browser.
Supporting Information
Figure S1 Reproducibility of ChIP-chip and related experi-
ments using the human SCL genomic tiling array. The figure
shows profiles generated from three independent biological
replicate experiments (shown as red, green and yellow joined-up
lines) for each of four different assays: histone H3 K9/K14ac
(panel a), GATA1 (panel b), FAIRE (panel c) and histone H3
(panel d). In each panel, the x-axis is the genomic sequence co-
ordinate (NCBI build 35) and the y-axis is the enrichment
obtained in ChIP-chip assays expressed in log2 scale. Schematic
diagram at the bottom of the figure shows the genomic
organisation of SCL and its neighbouring genes. Exons are shown
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as vertical blocks with gene names and direction of transcription
shown above. Transcripts denoted by a,b and c refer to transcripts
of unknown function (see also text). Vertical lines at the bottom
(with dotted lines through all the panels) show the location of
known and novel regulatory regions at the SCL locus. Promoters
are denoted by P. Other nomenclature refers to the distance in kb
from SCL promoter 1a. We assessed the performance of every
array element across multiple independent experiments; the mean
coefficient of variance (cv) in the ratios reported by array elements
ranged between 7–13% for all of the assays described in this paper.
Found at: doi:10.1371/journal.pone.0009059.s001 (0.90 MB TIF)
Figure S2 Comparison between enrichments obtained across
the human SCL locus by ChIP-chip with those obtained from real-
time SyBr Green PCR analysis of ChIP samples. (A) Histone H3
K9/K14ac in K562. (B) GATA1 in K562. Fold enrichments in
log2 scale are shown on the y-axis and datapoints across the locus
are shown on the x-axis for each histogram. Enrichments reported
by the array (grey bars) and those reported by real-time PCR
(black bars) are shown as pairs for each amplicon tested. Data in
panel a are ordered with respect to their genomic co-ordinates and
bracketed according to their location across the human SCL locus.
Data in panel b are ordered with respect to their level of ChIP
enrichments across the human SCL locus. See also Tables S6 and
S7 for genomic co-ordinates. The nomenclature of data points
refers to the distance in kb that the amplicon is located upstream
(2) or downstream (+) from the promoter of the closest gene.
NC = negative control regions.
Found at: doi:10.1371/journal.pone.0009059.s002 (0.76 MB TIF)
Figure S3 Profiles of binding for members of the SCL erythroid
transcription factor complex across the human SCL locus in the
K562 cell line. The transcription factors studied are named at the
left of each panel. E47 and E12 are isoforms of E2A. Dots on the
joined-up lines represent the data obtained for each genomic tiling
array element. In each panel, the x-axis is the genomic sequence
co-ordinate (NCBI build 35) and the y-axis is the enrichment
obtained in ChIP-chip assays expressed in log2 scale. Schematic
diagram at the bottom of the figure shows the genomic
organisation of SCL and its neighbouring genes. Exons are shown
as vertical blocks with gene names and direction of transcription
shown above. Transcripts denoted by a, b and c refer to transcripts
of unknown function. Vertical lines at the bottom (with dotted
lines through all the panels) show the location of known and novel
regulatory regions at the SCL locus. Promoters are denoted by P.
Other nomenclature refers to the distance in kb from SCL
promoter 1a.
Found at: doi:10.1371/journal.pone.0009059.s003 (0.96 MB TIF)
Figure S4 Correlation of nucleosome density and chromatin
fractionation (FAIRE) assay across the human SCL locus.
Datapoints for each array tile are plotted as a function of
chromatin fractionation/FAIRE (y-axis) and nucleosome density
(x-axis). All data are plotted as log2 values. Nucleosome densities
are derived as the mean value obtained from ChIP-chip analysis of
histone H3 and H2B. A strong negative correlation between
nucleosome density and chromatin fractionation was obtained
with a correlation co-efficient of R = -0.861.
Found at: doi:10.1371/journal.pone.0009059.s004 (0.52 MB TIF)
Figure S5 Conserved transcription factor binding sites found at
the novel -13 regulatory region. Sequence alignments are shown
for human, chimp, mouse, rat and dog. Genomic sequence co-
ordinates for each region of homology are shown in brackets
(taken from their respective genome builds). Bases of sequence
identity are denoted with an asterisk (*). Site for ETV6/7 (TEL1/
2) is boxed in bold. Sites are shown (boxed) for a variety of other
transcription factors including Sp1, PEA3, ETS-1, GR (glucocor-
ticoid receptors), RAR-x (retinoic acid receptors), AP1 (activator
proteins), and NFAT-x (nuclear factors of activated T cells).
Found at: doi:10.1371/journal.pone.0009059.s005 (0.65 MB TIF)
Figure S6 Conserved transcription factor binding sites found at
the human SCL +51 erythroid enhancer. Sequence alignments are
shown for human, chimp, mouse, rat and dog. Genomic sequence
co-ordinates for each region of homology are shown in brackets
(taken from their respective genome builds). Bases of sequence
identity are denoted with an asterisk (*). Sites for GATA1 (and
other family members), the SCL erythroid transcriptional complex
are boxed in bold. Sites are shown (boxed) for a variety of other
transcription factors including Sp1, E12, MyoD (E-box), RAR-x
(retinoic acid receptors), and AP-1,2,4 (activator proteins).
Found at: doi:10.1371/journal.pone.0009059.s006 (0.74 MB TIF)
Figure S7 Binding of members of the SCL erythroid complex to
the +51 region in the erythroid HEL 92.1.7 cell line. Histogram
shows the ChIP enrichments obtained for GATA1, E2A (E12 and
E47), SCL, LDB1 and LMO2 at +51 (black bars). Grey bars show
the value equal to two standard deviations above the mean ChIP
enrichments for a series of negative control regions (NCi - Ncxi as
in Figure S2a) across the SCL locus. Primer pairs for these
negative control regions and +51 are shown in Tables S6 and S7.
Found at: doi:10.1371/journal.pone.0009059.s007 (0.60 MB TIF)
Figure S8 Expression of transcripts of unknown function at the
+53 region in the K562 cell line. Histogram shows real-time SyBr
green quantitative PCR results of transcripts a, b and c expressed
in log10 scale relative to the level of expression of SCL (SCL is
assigned an arbitrary level of expression). PCR amplifications from
samples which were reverse transcribed into cDNA are shown as
black bars. Amplicon for transcripts a and b was from coding
sequence shared by both transcripts - thus expression results for
these are presented collectively as a/b. Negative controls for PCR
amplification in the absence of reverse transcription are shown as
grey bars.
Found at: doi:10.1371/journal.pone.0009059.s008 (0.55 MB TIF)
Figure S9 Schematic diagram of the biological events identified
at the human SCL erythroid enhancer in the K562 cell line. At the
top of the figure, DNA is shown as the black line wrapped around
nucleosomes (blue/grey spheres). Regions of accessible chromatin
are shown as regions with fewer nucleosomes per unit length of
DNA. Location of transcription factors, RNApolII and TAFII 250
are shown by larger grey and black spheres and ovoids. Histone
modifications are shown as flags on the nucleosomes and are
histone H3 K9/K14ac (Ac), histone H3 K4me3 (3 M), histone H3
K4me2 (2 M), and histone H3 K4me1 (1M). The four kb block of
genomic DNA (+50 to +53) shown at the bottom half of the figure
is numbered in one kb intervals according to distance in kb from
the SCL pro1a. Genomic sequence co-ordinates are from NCBI
build 35. The core erythroid enhancer at +51 is shown as the black
horizontal bar and the extent of the bar defines the region which
drives enhancer activity in transient reporter assays (see Figure 4).
The bidirectional promoter at +53 is shown as the black horizontal
bar with arrowheads and the bar extent defines the region which
has bidirectional promoter activity in transient reporter assays.
Found at: doi:10.1371/journal.pone.0009059.s009 (1.26 MB TIF)
Table S1 Array elements which show significant enrichments for
each member of the SCL erythroid complex in K562 cells. The
names of array elements shown in the third column are as
described in Table S2. Significant enrichments derived as the
mean ratio from multiple experiments are shown in log2 scale in
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the second column. Genomic sequence co-ordinates are from
NCBI build 35.
Found at: doi:10.1371/journal.pone.0009059.s010 (0.09 MB
DOC)
Table S2 Oligonucleotide primer pairs used to PCR amplify
array elements for the human SCL tiling array. Amplicon names
used in our laboratory are shown in the first column. Amplicon
sizes and genomic sequence co-ordinates are from NCBI build 35.
Found at: doi:10.1371/journal.pone.0009059.s011 (0.60 MB
DOC)
Table S3 Antibodies used for ChIP-chip assays performed in
this study. Antibodies for histone modifications, transcription
factors, histones and antisera controls are listed along with their
supplier and catalogue numbers.
Found at: doi:10.1371/journal.pone.0009059.s012 (0.05 MB
DOC)
Table S4 Oligonucleotide primer pairs used to PCR amplify the
regions cloned into the pGL3 luciferase reporter constructs.
Construct names in the first column are as described in Figure 4.
The BamHI, Kpn1 and HindIII sites added to the sequence of
each primer are shown in brackets. Amplicon sizes and genomic
sequence co-ordinates are from NCBI build 35.
Found at: doi:10.1371/journal.pone.0009059.s013 (0.03 MB
DOC)
Table S5 Oligonucleotide primer pairs used to PCR amplify the
regions cloned into the enhancer blocking reporter constructs.
Construct names in the first column are as described in Figure 4.
The AscI sites added to the sequence of each primer are shown in
brackets. Amplicon sizes and genomic sequence co-ordinates are
from NCBI build 35.
Found at: doi:10.1371/journal.pone.0009059.s014 (0.03 MB
DOC)
Table S6 Oligonucleotide primer pairs used to perform SyBr
green quantitative real-time PCR for regions enriched for histone
H3 K9/K14ac. Amplicon names in the first column are as shown
in Figure S2 (panel a) while the second column lists alternative
names which describe corresponding amplicons found in Table
S2. Amplicon sizes and genomic sequence co-ordinates are taken
from NCBI build 35.
Found at: doi:10.1371/journal.pone.0009059.s015 (0.12 MB
DOC)
Table S7 Oligonucleotide primer pairs used to perform SyBr
green quantitative real-time PCR for regions enriched for
GATA1. Amplicon names in the first column are as described in
Figure S2 (panel b) while the second column lists alternative names
which describe corresponding amplicons found in Table S2.
Amplicon sizes and genomic sequence co-ordinates are from
NCBI build 35.
Found at: doi:10.1371/journal.pone.0009059.s016 (0.04 MB
DOC)
Table S8 Oligonucleotide primer pairs used to perform SyBr
green quantitative real-time PCR to detect reverse-transcribed
cDNA for transcripts a, b and c of unknown function. Amplicon
for transcripts a and b was from coding sequence shared by both
transcripts - thus one amplicon represents both transcripts. The
primer pairs for SCL and b-actin are also shown. Alternative
names for the primer pairs are shown. Amplicon sizes and
genomic sequence co-ordinates are taken from NCBI build 35.
n.a. = not applicable.
Found at: doi:10.1371/journal.pone.0009059.s017 (0.03 MB
DOC)
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